← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs
xaliproden
N07XX03
Forms & Strengths
- Oral capsule (investigational)
Adult Dosing
- Investigational agent; no approved clinical dosage regimens established
- Evaluated in clinical trials for amyotrophic lateral sclerosis (ALS) at various doses (e.g., 1 mg to 2 mg daily)
Pediatric Dosing
- Not evaluated or indicated for pediatric populations
Indications
- Investigated for the treatment of amyotrophic lateral sclerosis (ALS)
- Previously explored for neurodegenerative conditions
Mechanism of Action
- Non-peptide 5-HT1A receptor agonist
- Induces synthesis and release of neurotrophic factors such as brain-derived neurotrophic factor (BDNF)
- Exerts potential neuroprotective and neurotrophic effects on motor neurons
Contraindications
- Known hypersensitivity to xaliproden or its excipients
- History of severe cardiovascular disease or arrhythmias in clinical trial exclusions
Adverse Reactions
- Dizziness
- Nausea
- Somnolence
- Asthenia
- Postural hypotension
Drug Interactions
- Potential pharmacodynamic interactions with other serotonergic agents (risk of serotonin syndrome)
- Additive hypotensive effects with antihypertensive medications
Curated Content: Needs Vetting Before Put to Clinical Use